Navigation Links
Tapestry Pharmaceuticals to Present Data on TPI 287 at the 2007,AACR Annual Meeting

BOULDER, Colo., March 14, 2007 /PRNewswire-FirstCall/ -- Tapestry Pharmaceuticals, Inc. today announced that it will present new data at the 2007 American Association for Cancer Research (AACR) Annual Meeting, April 14-18 in Los Angeles, Calif. Scientists from Tapestry Pharmaceuticals will discuss preclinical data on the Company's lead compound, TPI 287, in a poster presentation entitled, "TPI 287 crosses the blood brain barrier and contributes to antitumor activity in the U251 glioblastoma intracranial tumor model in nude mice." The poster (#1441) will be presented Sunday, April 15, 2007 from 1:00 - 5:00 p.m. at the Experimental and Molecular Therapeutics 8 session.

About TPI 287

TPI 287, a proprietary next generation taxane, is Tapestry's lead clinical compound. This compound was designed to overcome multi-drug resistance in solid tumors that have become resistant to taxane therapy. In preclinical testing, TPI 287 demonstrated the ability to inhibit tumor cell growth in a number of in vitro cell lines and in general, has shown equivalent inhibition of tumors in certain animal xenograft models when tested against standard comparative agents. In some cell lines resistant to taxanes, TPI 287 has demonstrated greater inhibition of tumors in certain animal xenograft models when tested against standard comparative agents. The in vitro activity was seen across multiple cell lines including cell lines known to be sensitive to taxanes and cell lines known to be resistant to taxanes. Taxane sensitive cell lines in which TPI 287 has shown activity include cell lines derived from breast cancer, uterine cancer and non-small cell lung cancer. Taxane resistant cell lines in which TPI 287 shows greater activity include lines derived from breast and colon cancer. In in vivo testing TPI 287 demonstrated greater tumor growth inhibition activity in tumor cell lines with multiple drug resistance, MDR1.

TPI 28
'"/>




Page: 1 2 3 4

Related medicine technology :

1. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
2. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
4. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
5. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
6. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
7. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
8. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
9. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
10. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
11. Arisaph Pharmaceuticals Announces Results of its Potent Smart DPP-4 Inhibitor, ARI-2243, at the ADA
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Tapestry Pharmaceuticals Present Data TPI the AACR Annual Meeting
(Date:9/15/2014)... Sept. 15, 2014 PDL BioPharma, Inc. (PDL) (NASDAQ: ... paid the September 12, 2014, regular quarterly dividend payment of ... PDL as of September 5, 2014, the record date. ... manages a portfolio of patents and royalty assets, consisting ... and license agreements with various biotechnology and pharmaceutical companies. ...
(Date:9/15/2014)... Sept. 15, 2014 Research and Markets ... Drug Transfer Systems to 2020" report to their ... hazardous to humans has been receiving increasing amounts of ... substances become more clearly understood. For caregivers and their ... of attempts to mitigate exposure to cytotoxic drugs is ...
(Date:9/15/2014)... -- Research and Markets has announced the addition ... Tests, 9th Edition" report to their offering. ... testing market and all of its segments, providing customers with ... For Business Planning. This is the ninth edition ... 2013 and early 2014. New entrants, new technologies have entered ...
Breaking Medicine Technology:PDL BioPharma Completes Regular Quarterly Dividend Payment 2Closed Drug Transfer Systems to 2020 2Closed Drug Transfer Systems to 2020 3The Worldwide Market for In Vitro Diagnostic Tests, 9th Edition 2The Worldwide Market for In Vitro Diagnostic Tests, 9th Edition 3
... 17, 2011 Attorneys representing a group of U.S. citizens ... the drug thalidomide have filed a lawsuit in federal court ... show the drug was widely distributed in the United States. ... to respond to a number of Freedom of Information Act ...
... WASHINGTON, Nov. 17, 2011 The proliferation of brand ... generics to more expensive brands, will increase costs by ... employers, unions, and state employee plans, according to new ... Care Management Association (PCMA).   The use of these ...
Cached Medicine Technology:Hagens Berman: Patients Seek to Force FDA to Release Records Showing US Distribution of Thalidomide 2Hagens Berman: Patients Seek to Force FDA to Release Records Showing US Distribution of Thalidomide 3Brand Drug 'Copay Coupons' Undermine Generics, Raise Health Costs by $617 Million in Wisconsin 2
(Date:9/15/2014)... York, New York (PRWEB) September 15, 2014 ... C.R. Bard, Inc. continue to move forward in the ... Southern District of West Virginia, Bernstein Liebhard LLP reports. ... issued a Final Order on September 10th that provides ... The Order notes that none of the affected plaintiffs ...
(Date:9/15/2014)... studies, approximately one out of every 40 individuals in the ... spinal muscular atrophy (SMA), a neurodegenerative disease that causes muscles ... Missouri have made a recent breakthrough with the development of ... models of the disease. In April, a patent was filed ... our lab is using to fight SMA is to ,repress ...
(Date:9/15/2014)... 2014 This year, Avenidas Village ... 2007. To mark the special occasion, Avenidas Village would ... village and helping it to get started seven years ... fun community for seniors. Members of Avenidas Village maintain ... in their own homes. They are able to have ...
(Date:9/15/2014)... Sept. 15, 2014 (HealthDay News) -- Births of multiple ... and death than singleton births, researchers report. The ... in vitro fertilization (IVF) could ease some of that ... have increased in tandem with births to older mothers ... from the University of New South Wales, Australia. ...
(Date:9/15/2014)... 2014 Providing additional expertise to ... LLP (“the Firm”) is proud to welcome ... with the Firm’s Litigation Support Services ... experience, Wolf will assist clients in litigation support, ... advisory matters. He will also provide guidance in ...
Breaking Medicine News(10 mins):Health News:C.R. Bard Transvaginal Mesh Lawsuits Move Forward, With Issuance of New Order in Federal Multidistrict Litigation, Bernstein Liebhard LLP Reports 2Health News:C.R. Bard Transvaginal Mesh Lawsuits Move Forward, With Issuance of New Order in Federal Multidistrict Litigation, Bernstein Liebhard LLP Reports 3Health News:Researcher develops and proves effectiveness of new drug for spinal muscular atrophy 2Health News:Avenidas Village Celebrates Anniversary 2Health News:Study Ties Multiple Births to Higher Costs, Complications 2Health News:Study Ties Multiple Births to Higher Costs, Complications 3Health News:Cherry Bekaert Expands its Litigation Support Services Team Capabilities with the Addition of Steven Wolf 2Health News:Cherry Bekaert Expands its Litigation Support Services Team Capabilities with the Addition of Steven Wolf 3
... Over time, they boost risk for ulcers and even amputation, ... Something as simple as wearing the wrong size of shoes ... could lead to amputation, Scottish researchers say. , The study, ... diabetes patients, ages 24 to 89, who had their feet ...
... The use of a pedometer and a Web site that ... people with diabetes who participated in a recent walking study ... and VA Ann Arbor Healthcare System. The study also suggests ... others. , All participants in the study wore pedometers and ...
... most harmful strains of human papillomavirus is under study ... called nine-valent, is being compared with Gardasil, a quadrivalent ... two most deadly HPV types. , Were testing Gardasil ... Dr. Daron Ferris, family medicine physician and director of ...
... Researchers here have shown that in cell cultures, ... signals that stimulate certain tumor cells to grow and ... a way of slowing the progression and spread of ... have a better chance to work. , The ...
... Family Caregiver,s Month; Announces Availability ... More than 34 Million Caregivers, PALO ALTO, Calif., Nov. ... proud to support the more than 34 million,Americans caring for ... availability of its website. Designed to give caregivers the ...
... BAY, Wis., Nov. 19 Shopko announced today plans,to ... the fall of 2008. The,stores will be located in ... the continuation of an exciting growth,phase for Shopko," said ... Earlier this year Shopko broke ground on the first ...
Cached Medicine News:Health News:Ill-Fitting Shoes a Danger to Diabetics 2Health News:Pedometers motivate people with diabetes to walk more 2Health News:Pedometers motivate people with diabetes to walk more 3Health News:New HPV vaccine under study 2Health News:Stress hormone may hasten the progression of certain blood cancers 2Health News:Stress hormone may hasten the progression of certain blood cancers 3Health News:Resource to Help Care for Aging Parents Now Available Nationwide 2Health News:Resource to Help Care for Aging Parents Now Available Nationwide 3Health News:Shopko Announces Plans for Two New Stores 2
... is a threaded titanium anchor, ... procedures. The anchor features wide ... to optimize bone purchase, as ... to prevent suture binding. Fastin ...
The GII titanium anchor is the "Gold Standard" for soft tissue reattachment to bone. The GII's small size, high pull-out strength and wide range of clinical applications make it the anchor of choice ...
... 'proximal protection' -- providing complete protection from ... vessels with side branches. , ,Proxis ... does not require the attachment or exchange ... debris. ,Proxis is compatible with all ...
... System is the Fischer answer to cost ... specialist. The EP-X system is a highly ... dedicated EP lab system. Ease of access ... Pulsed Progressive Fluoroscopy (PPF) are but a ...
Medicine Products: